Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 5/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.41 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754762 | 0.85 | KMT2A (0.50) | IDH1MEN1KMT2ACA1CA2 | |
| SCHEMBL25754703 | 0.84 | CYP19A1 (0.44) | IDH1MEN1KMT2ACA1CA2 | |
| SCHEMBL25754707 | 0.84 | MAPT (0.54) | IDH1MEN1KMT2AMAPT | |
| SCHEMBL23832730 | 0.84 | MOGAT2 (0.48) | FFAR4KIF11MEN1ALOX15MAPK1 | |
| SCHEMBL25754730 | 0.82 | MEN1 (0.61) | IDH1MEN1ALOX15MAPK1KMT2A | |
| SCHEMBL25754835 | 0.80 | IDH1 (0.53) | IDH1FFAR4KIF11MEN1ALOX15 | |
| SCHEMBL4596394 | 0.78 | CA2 (0.66) | FFAR4MEN1ALOX15MAPK1KMT2A | |
| SCHEMBL25754764 | 0.77 | ALPL (0.44) | IDH1KMT2AMAPT | |
| SCHEMBL5228757 | 0.75 | ALDH1A1 (0.70) | MEN1ALOX15MAPK1KMT2ACA1 | |
| SCHEMBL25754766 | 0.75 | SMN1; SMN2 (0.53) | MEN1ALOX15KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | IDH1 442/4885FFAR4 3109/4885KIF11 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.